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Earlier we identified adenosine monophosphate (AMP) N1-oxide as a unique compound of
royal jelly (RJ) that induces neurite outgrowth (neuritegenesis) from cultured rat pheochro-
mocytoma PC12 cells via the adenosine A2A receptor. Now, we found that AMP N1-oxide
stimulated the phosphorylation of not only mitogen-activated protein kinase (MAPK) but also
that of cAMP/calcium-response element-binding protein (CREB) in a dose-dependent manner.
Inhibition of MAPK activation by a MEK inhibitor, PD98059, did not influence the AMP
N1-oxide-induced neuritegenesis, whereas that of protein kinase A (PKA) by a selective
inhibitor, KT5720, significantly reduced neurite outgrowth. AMP N1-oxide also had the activity
of suppressing the growth of PC12 cells, which correlated well with the neurite outgrowth-
promoting activity. KT5720 restored the growth of AMP N1-oxide-treated PC12 cells. It is well
known that nerve growth factor suppresses proliferation of PC12 cells before causing
stimulation of neuronal differentiation. Thus, AMP N1-oxide elicited neuronal differentiation
of PC12 cells, as evidenced by generation of neurites, and inhibited cell growth through
adenosine A2A receptor-mediated PKA signaling, which may be responsible for characteristic
actions of RJ.
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Introduction
Royal jelly (RJ), which is fed to the queen honeybee, has
been reported to have a variety of biological activities
towards various types of cells (1–4). Although there are
few reports so far showing the effects of RJ on the
nervous system, we recently found that an extract of RJ
induces neurites from cultured PC12 cells, a cell line of
rat pheochromocytoma, and identified adenosine
monophosphate (AMP) N1-oxide as one of the active
components (5). AMP N1-oxide is a unique compound
not found in natural products other than RJ; and it
suppresses the proliferation of PC12 cells and stimulates
the expression of neurofilament M, a protein of mature
neurons, thus demonstrating that AMP N1-oxide induces
neuronal differentiation of PC12 cells (5), as does nerve
growth factor (NGF), a well-known neurotrophic factor
that affects PC12 cells. In response to the binding of
NGF to receptors p75 and TrkA, PC12 cells stop
dividing and extend neurites, differentiating into neurons
similar to those found in sympathetic neurons (6). NGF
triggers mainly two cascades of cellular signaling that
mediate neurite outgrowth, neurofilament M expression
and cell survival, i.e. mitogen-activated protein kinase
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properly cited.(MAPK)/extracellular signal-regulated kinase 1 or 2
(ERK1/2) and phosphatidylinositol 3-kinase/Akt path-
ways (6,7).
The neurite outgrowth-promoting activity of AMP
N1-oxide was found to be mediated by adenylate
cyclase-coupled adenosine A2A receptors (5). Adenosine
A2A receptor activation leads to an increase in the cAMP
level followed by activation of protein kinase A (PKA)
and extracellular signal-regulated kinase 1 or 2 (ERK1/2)
in PC12 cells (8,9). Activation of ERK1/2 is a checkpoint
to assess the activation of the Ras/MAPK cascade.
Moreover cAMP elevation induces the development of
neurites similarly as treatment with NGF (9). Forskolin,
an activator of adenylate cyclase, increases the cAMP
level, whose increase is in turn followed by neuronal
differentiation (10). Also, the rescuing effect of
A2A receptor-mediated cAMP/PKA signals was reported
in the case of NGF-induced neurite outgrowth from
PC12 cells impaired by suppression of the MAPK
cascade (11).
Therefore, in this study, we focused on elucidating
the intracellular signaling by AMP N1-oxide responsible
for stimulation of neurite outgrowth and/or sup-
pression of cell growth. Also, we speculated about the
action of AMP N1-oxide in RJ toward the nervous
system.
Materials and Methods
Materials
AMP N1-oxide was chemically synthesized (5). The
adenosine A2A receptor antagonist ZM241385 and
epidermal growth factor (EGF) were purchased from
Sigma (St. Louis, MO). The PKA inhibitor KT5720
was purchased from Biomol GmbH (Hamburg,
Germany). The MEK inhibitor PD98059 came from
Wako, and the Trk inhibitor K252a, from Santa
Cruz Biotechnology (Santa Cruz, CA). NGF was puri-
fied from mouse submaxillary glands as described
previously (12).
Assessments of Neurite Outgrowth and Cell Growth
PC12 cells were maintained in Dulbecco’s Modified
Eagle’s Medium supplemented with 10% horse serum
and 5% fetal bovine serum (6). For assessment of neurite
outgrowth, cells were plated at 10
4–10
5 cells/well in six
well plates coated with collagen. The cells were exposed
to test agents 1day after plating, and morphological
changes were observed under a phase-contrast micro-
scope. Neurite-bearing cells were defined as those with
processes longer than the length of the cell body. Four
areas, each containing 100–200 cells, were randomly
selected in each well, and the neurite-bearing cells
were counted. Cell proliferation was evaluated by
counting the total cell number, or by incorporation of
5-bromodeoxyuridine (BrdU) (Sigma) as described (13).
Cells were cultured on cover glasses coated with poly-
l-lysine and collagen in medium containing test samples.
The cultures were incubated for another 4h after the
addition of BrdU (10mM), fixed with 4% paraformalde-
hyde, and reacted with Alexa Fluor
TM-conjugated
anti-BrdU antibody (Sigma). For estimating total cell
number, cell nuclei were stained with propidium iodide
(Invitrogen, Carlsbad, CA).
Western Blotting
PC12 cells were lysed with lysis buffer [20mM Tris-HCl
buffer, pH 7.4, containing 150mM NaCl, 2mM EDTA,
1% NP-40, 10mg/ml aprotinin, 10mg/ml leupeptin,
50mM NaF, 1mM Na3VO4, 1mM phenylmethylsulfo-
nyl fluoride, 0.1% sodium dodecyl sulfate (SDS) and
1% Na deoxycholate]. The lysates were centrifuged, and
the protein concentration of each supernatant was
determined with a BCA Protein Assay Kit (Pierce,
Rockford, IL). Each sample (5mg of protein) was
subjected to SDS-polyacrylamide gel electrophoresis
(PAGE) on a 10% gel. Proteins were transferred to a
polyvinylidene fluoride membrane and blocked with 5%
skim milk (Morinaga Milk Products, Tokyo, Japan).
Next the membranes were incubated with primary
antibody at 4C overnight, washed and then reacted
with alkaline phosphatase-conjugated secondary anti-
body at room temperature for 1h (Promega, Madison,
WI). Finally, the protein bands were developed with
nitro blue tetrazolium and 5-bromo-4-chloro-3-indoryl-
phosphate p-toluidine salt. The primary antibodies used
were those against p44/42 MAPK, phospho-p44/42
MAPK, cAMP-response element-binding protein
(CREB) and phospho-CREB (Cell Signaling
Technology, Danvers, MA).
Immunoprecipitation
AMP N1-oxide or NGF was added to PC12 cell cultures,
which were then incubated for 10min, 1h or 2h. The
cells were washed with ice-cold PBS, and lysed with the
lysis buffer. The cell lysates were incubated overnight at
4C with anti-Trk antibody (C-14; Santa Cruz
Biotechnology), followed by incubation with protein
A-Sepharose beads (Amersham Pharmacia Biotech, IL)
for 1h at 4C. The pellet was then collected, washed
with the lysis buffer, and subjected to SDS-PAGE.
Phosphorylated TrkA was detected by Western blotting
with anti-phosphotyrosine antibody (Santa Cruz
Biotechnology).
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Correlation Between Antimitotic Activity and Neurite
Outgrowth-promoting Activity
AMP N1-oxide at concentrations between 1 and 33mM
induced neurite outgrowth from PC12 cells in a dose-
dependent manner (Fig. 1A) similarly as shown earlier
(5). On the other hand, when the antimitotic effect of
AMP N1-oxide on PC12 cells was examined by using the
BrdU-labeling method, the ratio of BrdU-positive cells to
total cells decreased with an increase in the concentration
of AMP N1-oxide (Fig. 1B). At the highest concentration
tested (33mM), AMP N1-oxide reduced the ratio of
BrdU-positive cells to nearly 2%, but induced the
maximal neurite outgrowth. Namely, the rate of cell
proliferation was inversely related to the degree of neurite
outgrowth. In other words, the antimitotic activity of
AMP N1-oxide may be critical for the neurite outgrowth-
promoting activity by this molecule.
Phosphorylation of CREB and MAPK by AMP N1-oxide
We first examined the phosphorylation of CREB in
response to AMP N1-oxide, since we had earlier shown
that the actions of AMP N1-oxide were mediated by the
adenylcyclase-coupled adenosine receptor A2A (5). As
Fig. 2A shows, phosphorylation of CREB was increased
dose dependently by AMP N1-oxide up to 500mM, and
diminished by the selective A2A receptor antagonist
ZM241385 (Fig. 2B), suggesting that the phosphorylation
of CREB was evoked by AMP N1-oxide through A2A
receptor-mediated PKA activation.
MAPK was also phosphorylated in a dose-dependent
manner by AMP N1-oxide from 4 to 500mM (Fig. 3A).
The MEK inhibitor PD98059 or A2A receptor antagonist
ZM241385 clearly inhibited the phosphorylation of
MAPK, whereas the PKA inhibitor KT5720 did not
affect it even when administered at concentrations higher
than 2mM (Fig. 3B), demonstrating that MAPK phos-
phorylation was evoked through A2A receptor-mediated
MEK activation independent of PKA activity.
Involvement of MAPK or PKA Signaling in the Action
Mechanism of AMP N1-oxide
Involvement of MAPK activation in neurite outgrowth
was next examined. The MEK inhibitor PD98059 did
not inhibit AMP N1-oxide-induced neurite outgrowth
(Fig. 4A), suggesting the induced outgrowth to be inde-
pendent of the MAPK signaling pathway. The suppression
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Figure 1. Reciprocal relationship between neurite outgrowth (A) and cell growth (B) of AMP N1-oxide-treated PC12 cells. PC12 cells were cultured
for 1day in medium containing AMP N1-oxide. A: the ratio of the number of cells with neurite to total cells was calculated. The values are expressed
as the meanstandard error (n=3). Significant differences from non-treated cells were determined by one-way ANOVA with Tukey’s test,
***P<0.001, **P<0.01. B: PC12 cells were incubated for 4h with BrdU (10mM), fixed, and reacted with Alexa Fluor
TM-conjugated anti-BrdU
antibody. The number of BrdU-positive cells was counted, and the ratio of positive cells to total cells was calculated. The values are expressed as the
meanstandard error (n=4). Significant differences versus the non-treated control were determined by one-way ANOVA with Tukey’s test,
***P<0.001, **P<0.01.
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Figure 2. Phosphorylation of CREB in PC12 cells after treatment with
various agents. PC12 cells were cultured for 30min in medium
supplemented with various concentrations of AMP N1-oxide (A)o ri n
medium supplemented or not with 20mMA M PN1-oxide in the
presence or absence of various concentrations of KT5720 or ZM 241385
for 30min (B). The cell lysates were subjected to PAGE (5mg protein/
lane) and blotted onto membranes for Western blotting with anti-
phosphorylated-CREB and anti-CREB antibodies.
eCAM 2010;7(1) 65of cell growth was not dependent on MAPK, either, since
the growth of PC12 cells was also slow when cells were
treated with AMP N1-oxide and PD98059at the same
time. However, the PKA inhibitor KT5720 significantly
reduced a percentage of the cells with the AMP N1-oxide-
induced neurites (Fig. 4A), and simultaneously attenuated
the AMP N1-oxide-induced suppression of cell prolifera-
tion (Fig. 4B). These observations suggest the participa-
tion of PKA signaling not only in the neuritegenic
activity of AMP N1-oxide but also in its cell growth-
suppressing activity.
Interaction of the Action Mechanism of AMP N1-oxide
with TrkA Signal Pathway
Transactivation of mitogenic kinase receptors through G
protein-coupled receptors was described earlier (14,15).
Namely, adenosine and adenosine receptor agonists were
reported to activate Trk receptors through a mechanism
that requires the adenosine A2A receptor (16). Therefore,
we examined whether TrkA was activated during neurite
outgrowth by AMP N1-oxide. However, we could not
obtain any positive results indicating activation (data not
shown). Furthermore, treatment of cells with a selective
TrkA inhibitor, K252a, greatly reduced the phosphoryla-
tion level of MAPK of cells incubated with NGF, but the
level obtained with AMP N1-oxide was unaffected (data
not shown). The neurite outgrowth by AMP N1-oxide
was also unaffected by K252a. Thus, TrkA activation
seems not to be involved in the response of cells to AMP
N1-oxide.
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Figure 4. Effects of inhibitors of PKA and MAPK on the neurite outgrowth of AMP N1-oxide-treated PC12 cells (A) and on suppression of growth
of PC12 cells elicited by AMP N1-oxide (B). The cells were precultured for 30min in medium containing KT5720 (2mM) or PD98059 (100mM).
Then, AMP N1-oxide (20 or 100mM) was added, and the cells were cultured for another 1day. A: the number of process-bearing cells was counted,
and the ratio of them to total cells was calculated. The values are expressed as the meanstandard error (n=6). Significant difference from the non-
treated cells was determined by one-way ANOVA with Tukey’s test, *P<0.05. ‘ns’ means non-significant relationship. B: the cells were cultured for
4 days in medium containing the indicated concentrations of AMP N1-oxide and KT5720. The number of cells was then counted, and the values
expressed as the meanstandard error (n=3). Significant differences from the values of the corresponding cells untreated with the inhibitor were
determined by one-way ANOVA with Tukey’s test, ***P<0.001, **P<0.01, *P<0.05. Significance of differences in values between non-treated
control cells and the cells treated with 20mMA M PN1-oxide was determined by Student’s t-test, ***P<0.001.
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Figure 3. Phosphorylation of ERK1/2 in PC12 cells after treatment with
various agents. The cells were cultured in medium supplemented with
various concentrations of AMP N1-oxide for 10min (A) or in medium
supplemented or not with 20mMA M PN1-oxide in the presence or
absence of PD98059, KT5720 or ZM 241385 for 30min (B). The cell
lysates were subjected to PAGE (5mg protein/lane) and blotted onto
membranes for Western blotting with anti-phosphorylated- ERK1/2
and anti-ERK1/2 antibodies.
66 PKA-dependent neurite outgrowth by AMP N1-oxideDiscussion
Adenosine plays an essential role in modulating neuronal
function via adenosine receptors (17). In the central
nervous system (CNS), the A2A receptor gene is strongly
expressed and is suggested to be involved in the
regulation of synaptic plasticity and to play a critical
role in early neuronal development (18). In such a
context, adenosine derivatives may have various effects
on the CNS, and be expected to modulate brain
functions.
Here, we demonstrated that MAPK phosphorylation
was evoked through A2A receptor-mediated MEK activa-
tion in a manner independent of PKA signaling (Fig. 3).
Recently, Kim et al. (19) reported that secretin-induced
neurite outgrowth of PC12 cells and that the activity was
dependent on a cAMP-MAPK pathway. According to
them, a PKA inhibitor suppressed the phosphorylation
of MAPK, which is inconsistent with our results. MAPK
can be phosphorylated in response to cAMP in a manner
independent of PKA, whose phosphorylation is mediated
by the Rap1-B-Raf pathway (20) or an Src family kinase
(21). This pathway might be involved in the mechanism
of AMPN1-oxide-evoked MAPK activation.
Integrin signals activate the MAPK signaling pathway,
which is required for Mn
2+-induced neurite outgrowth of
PC12 cells (22). TrkA signals evoked by NGF also cause
MEK activation followed by MAPK phosphorylation
necessary for neurite outgrowth (23). Thus, it is obvious
that both Mn
2+- and NGF-induced neurite outgrowth
require activation of MAPK. However, AMP N1-oxide-
induced neurite outgrowth was independent of the
activation of the MAPK signaling pathway (Fig. 4).
This mechanism may be supported by A2A signal-
mediated activation of CREB, which is known to
induce neurite outgrowth without MAPK signaling (24).
In this study, we found that the AMP N1-oxide-induced
CREB phosphorylation dependently on A2A receptor-
mediated PKA signaling (Fig. 2). However, we have not
yet had direct evidence whether the CREB phosphoryla-
tion is correlated with neurite outgrowth or cell growth
suppression elicited by AMP N1-oxide.
Neuronal differentiation is accompanied by suppressed
cell proliferation as reported earlier (25). Although the
mechanism underlying cell growth suppression by AMP
N1-oxide is not known, we showed earlier that activities
of both cell growth suppression and neurite outgrowth
are mediated by the adenosine A2A receptor (5).
Other investigators recently identified translin-associated
protein X (TRAX) as a novel protein that interacts with
the C-terminal part of the adenosine A2A receptor, and
considered TRAX to be an essential molecule for
mediating A2A receptor-induced inhibition of cell pro-
liferation (26). It is likely that AMP N1-oxide interacts
with TRAX at higher affinity than does AMP. This
hypothesis may explain the preferential neurite outgrowth
by AMP N1-oxide. Thus, AMP N1-oxide may modulate
the activities of various neurotrophic factors through
TRAX and A2A receptors to a greater extent than AMP.
Therefore, AMP N1-oxide would be expected to have
beneficial effects on the CNS when used in combination
with other agents such as favorable neurotrophic factors.
AMP N1-oxide is a unique compound not found in
natural resources so far other than RJ. Therefore, it may
be the molecule responsible for RJ-specific physiological
actions on the CNS. Our study provides molecular-based
evidence that RJ regulates neuronal functions through
A2A receptor signaling enhanced by AMP N1-oxide.
We expect neuroprotective effects of AMP N1-oxide on
the brain as a potent agonist of A2A receptor, because
particular ligands of A2A receptors including selective
agonists are reported to protect neurons against kainate-
induced excitotoxicity in vivo (27) or to attenuate the A1
receptor-mediated synaptic depression in the CA1 area
of the hippocampus in vitro (28). In addition, A2A
receptor antagonists can also reduce damage produced by
combinations of sub-threshold doses of the endogenous
excitotoxin quinolinic acid and free radicals (29). These
observations suggest that up or down regulation of A2A
receptor-linked signaling pathway appear to be promising
for the prevention of neuronal damage (30). As A2A
receptors are predominantly expressed in dendrites of
medium spiny neurons of the striatum in rats, Cabeza
et al. (31) demonstrated that A2A receptor agonist, CGS-
21680, activated both ERK1/2 and CREB in the caudate-
putamen, suggesting that AMP N1-oxide modulates
neuronal signaling in various brain regions including
caudate-putamen.
Elucidation of the physiological roles of AMP N1-oxide
in brain function is important to develop RJ as an
evidence-based complementary and alternative medicine.
Taking RJ as a source of AMP N1-oxide may be
promising to maintain healthy brain functions.
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